The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness
This narrative review (2020) evaluates the therapeutic potential of psilocybin and MDMA for the treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and anxiety. The review explains the need for effective mental health treatments and highlights the lack of dose-response studies in placebo-controlled settings with a real-world clinical population.
Authors
- Roger McIntyre
- Jonathan Rosenblat
- Maria Rodrigues
Published
Abstract
Introduction: Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Indeed, the economic burden of mental illness is estimated to exceed $1.8 trillion USD over the next 30 years. A significant number of individuals affected by mental illness fail to respond to first-line treatment options. Therefore, there remains an unmet need for rapidly attenuating therapeutic options for mental health disorders with minimal social and economic burden.Areas covered: The paucity of novel treatment options warrants a renewed investigation of psychedelic-based psychotherapy. Herein, the authors will evaluate the therapeutic potential of traditional psychedelics, psilocybin and MDMA, in the treatment of mental illness with a narrative review of available literature.Expert opinion: Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety, tolerability and efficacy in clinically representative populations are warranted.
Research Summary of 'The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness'
Introduction
Mental illness imposes a large and growing social and economic burden, with many patients failing to respond to first-line treatments and an estimated economic cost projected to exceed $1.8 trillion USD over the next 30 years. Gill and colleagues situate their review in this context and describe a renewed interest in psychedelic-based psychotherapy—particularly psilocybin and MDMA—as potential rapid-acting treatments. The introduction summarises a historical arc from mid-20th century research through regulatory restrictions and a more recent ‘‘second wave’’ of clinical interest, noting preliminary signals of antidepressant, anxiolytic and psychotherapeutic benefit alongside uncertainties about mechanisms and safety. This paper sets out to evaluate the extant literature on psilocybin and MDMA with a narrative review approach, emphasising therapeutic potential, proposed mechanisms of action, safety and tolerability, and disorder-specific findings (major depressive disorder, anxiety disorders, OCD, and PTSD). The authors highlight a gap in large, placebo-controlled dose–response trials in clinically representative populations and indicate a need for further randomised studies to establish efficacy and safety profiles in real-world settings.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Gill, H., Gill, B., Chen-Li, D., El-Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y., Rosenblat, J. D., Majeed, A., Mansur, R. B., Nasri, F., Ho, R., & McIntyre, R. S. (2020). The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness. Expert Review of Neurotherapeutics, 20(12), 1263-1273. https://doi.org/10.1080/14737175.2020.1826931
References (30)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Greer, G. R. · Journal of Psychoactive Drugs (1986)
Dinis-Oliveira, R. J. · Drug Metabolism Reviews (2017)
Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Coyle, C. M., Laws, K. R. · Human Psychopharmacology (2015)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Show all 30 referencesShow fewer
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Sessa, B. · Neuroscience Letters (2016)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Gorman, I., Belser, A. B., Jerome, L. et al. · Journal of Traumatic Stress (2020)
Wilcox, C. E. · Journal of Psychoactive Drugs (2014)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Kuypers, K. P. C., de la Torre, R., Farré, M. et al. · Scientific Reports (2018)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Cited By (2)
Papers in Blossom that reference this study
Gill, H., Puramat, P., Patel, P. et al. · Psychiatry Research (2022)
Siegel, A. N., Lipsitz, O., Gill, H. et al. · Journal of Psychiatric Research (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.